Lantern Pharma Announces Significant Positive Preclinical Data in Pancreatic Cancer With Drug Candidate LP-184PRNewsWire • 07/20/21
Lantern Pharma Inc. (LTRN) CEO Panna Sharma on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/04/21
Lantern Pharma Reports First Quarter 2021 Financial Results and Operational HighlightsPRNewsWire • 05/03/21
Lantern Pharma and Actuate Therapeutics Announce Research & Development Collaboration Leveraging Lantern's Artificial Intelligence PlatformPRNewsWire • 05/03/21
Lantern Pharma's Proprietary A.I. Platform for Precision Oncology Drug Development, RADR®, Surpasses 4.6 Billion Datapoints, Accelerating the Company's Progress in the Development of Biopharma Collaborations and Partnerships and Advancing the Company's StPRNewsWire • 04/29/21
Lantern Pharma to Host First Quarter 2021 Operating and Financial Results Conference Call on May 3, 2021 at 4:30 p.m. ETPRNewsWire • 04/26/21
Lantern Pharma Announces Publication Detailing Preclinical Results of Drug Candidate, LP-184, in a Spectrum of Drug-Resistant Lung Cancers in the Journal OncotargetPRNewsWire • 04/26/21
Lantern: Changing The Cost-Curve, Changing The Risk, AI-Biotech Unlocks New ValueSeeking Alpha • 04/09/21
Lantern Pharma to Participate in the Virtual 20th Annual Needham Healthcare ConferencePRNewsWire • 04/06/21
Lantern Pharma Expands Portfolio of Cancer Opportunities for LP-184 with ATRT Pediatric Brain Tumor Collaboration with Johns HopkinsPRNewsWire • 04/01/21
Lantern Pharma to Present New Data Supporting the Advancement of LP-184 at the AACR Virtual Annual Meeting 2021PRNewsWire • 03/23/21
Lantern Pharma Announces Filing of Seven Patent Applications Globally on Novel DNA-Damaging Agent with Anticancer PropertiesPRNewsWire • 03/17/21
Lantern Pharma Interview to Air on Bloomberg TV in the US on the RedChip Money Report®PRNewsWire • 03/12/21
Lantern Pharma Inc. (LTRN) CEO Panna Sharma on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 03/11/21
Lantern Pharma Reports Fourth Quarter and Year End 2020 Financial Results and Operational HighlightsPRNewsWire • 03/10/21
Lantern Pharma CEO Discusses The Addition Of Its New ADC Program And The Resurgence Of ADC Therapy For Cancer TreatmentBenzinga • 02/22/21
Lantern Pharma Announces Closing of Public Offering of $69 Million USD and Full Exercise of Underwriter's Over-Allotment OptionPRNewsWire • 01/20/21
Lantern Pharma Announces Launch of Antibody Drug Conjugate (ADC) Program to Target Solid Tumors & Blood Cancers through Agreement with Califia PharmaPRNewsWire • 01/04/21